Denali Therapeutics (NASDAQ:DNLI) Upgraded at Baird R W

Baird R W upgraded shares of Denali Therapeutics (NASDAQ:DNLI) to a strong-buy rating in a research report released on Tuesday morning,Zacks.com reports.

Several other equities analysts also recently commented on the stock. Robert W. Baird initiated coverage on shares of Denali Therapeutics in a research note on Tuesday. They issued an “outperform” rating and a $31.00 price target on the stock. Stifel Nicolaus upgraded shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 target price on the stock in a research report on Monday, December 16th. HC Wainwright dropped their price target on shares of Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating for the company in a research report on Tuesday. William Blair assumed coverage on Denali Therapeutics in a research report on Friday, January 3rd. They set an “outperform” rating on the stock. Finally, Jefferies Financial Group raised their price objective on Denali Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. Two analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $38.91.

Denali Therapeutics Stock Performance

Shares of DNLI stock opened at $21.25 on Tuesday. Denali Therapeutics has a 52 week low of $14.56 and a 52 week high of $33.33. The company has a market capitalization of $3.06 billion, a price-to-earnings ratio of -7.70 and a beta of 1.39. The company has a 50-day simple moving average of $24.23 and a 200 day simple moving average of $24.86.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter in the prior year, the business earned ($0.72) earnings per share. Sell-side analysts forecast that Denali Therapeutics will post -2.71 EPS for the current year.

Insider Activity at Denali Therapeutics

In other Denali Therapeutics news, Director Vicki L. Sato sold 1,020 shares of the stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $30.00, for a total value of $30,600.00. Following the completion of the transaction, the director now directly owns 111,056 shares in the company, valued at approximately $3,331,680. This trade represents a 0.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Ryan J. Watts sold 40,000 shares of the business’s stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $27.69, for a total value of $1,107,600.00. Following the sale, the chief executive officer now owns 235,807 shares in the company, valued at approximately $6,529,495.83. This trade represents a 14.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 104,518 shares of company stock valued at $2,576,982 over the last ninety days. 7.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP grew its position in shares of Denali Therapeutics by 9.2% in the 3rd quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company’s stock valued at $312,491,000 after buying an additional 903,683 shares during the last quarter. FMR LLC lifted its stake in shares of Denali Therapeutics by 3,234.3% in the third quarter. FMR LLC now owns 7,831,378 shares of the company’s stock worth $228,128,000 after acquiring an additional 7,596,508 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Denali Therapeutics by 63.2% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,749,486 shares of the company’s stock valued at $109,223,000 after acquiring an additional 1,451,770 shares during the last quarter. Marshall Wace LLP increased its position in Denali Therapeutics by 12.7% during the 2nd quarter. Marshall Wace LLP now owns 2,418,833 shares of the company’s stock valued at $56,165,000 after purchasing an additional 272,454 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in Denali Therapeutics by 6.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,417,472 shares of the company’s stock valued at $32,913,000 after purchasing an additional 84,522 shares during the period. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.